SYROS PHARMACEUTICALS INC's ticker is SYRS and the CUSIP is 87184Q107. A total of 12 filers reported holding SYROS PHARMACEUTICALS INC in Q2 2016. The put-call ratio across all filers is - and the average weighting 2.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $243,000 | -34.0% | 25,000 | 0.0% | 0.01% | -57.1% |
| Q3 2017 | $368,000 | -49.7% | 25,000 | -45.1% | 0.01% | -54.8% |
| Q2 2017 | $732,000 | +14.9% | 45,500 | +13.8% | 0.03% | +24.0% |
| Q1 2017 | $637,000 | +6.9% | 40,000 | -18.4% | 0.02% | -13.8% |
| Q4 2016 | $596,000 | -12.4% | 49,000 | 0.0% | 0.03% | -31.0% |
| Q3 2016 | $680,000 | -18.3% | 49,000 | +6.9% | 0.04% | -34.4% |
| Q2 2016 | $832,000 | – | 45,857 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Flagship Ventures Fund IV General Partner LLC | 4,806,656 | $87,241,000 | 14.92% |
| Aisling Capital LLC | 908,565 | $16,490,000 | 3.89% |
| Foresite Capital Management III, LLC | 150,000 | $2,723,000 | 1.87% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,095,220 | $38,028,000 | 1.50% |
| Redmile Group, LLC | 946,182 | $15,058,000 | 1.44% |
| Casdin Capital, LLC | 50,000 | $908,000 | 0.90% |
| Eventide Asset Management | 150,000 | $2,723,000 | 0.17% |
| Weiss Multi-Strategy Advisers LLC | 45,857 | $832,000 | 0.06% |
| Baker Brothers Advisors | 204,465 | $3,711,000 | 0.04% |
| Alyeska Investment Group, L.P. | 70,000 | $1,271,000 | 0.01% |